The value of non-human primates in the development of monoclonal antibodies

Nature Biotechnology

Volumn 31, Issue 10, 2013, Pages 882-883

  Van Meer, P J K ^a   Kooijman, M ^b   Van Der Laan, J W ^c   Moors, E H M ^b   Schellekens, H ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CANAKINUMAB; CATUMAXOMAB; CERTOLIZUMAB PEGOL; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; NATALIZUMAB; PALIVIZUMAB; RANIBIZUMAB; VOTUMUMAB;

ARTICLE; BIOTECHNOLOGY; CALLITRICHINAE; CHIMPANZEE; CHLOROCEBUS; IMMUNOGENICITY; MACACA FASCICULARIS; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIMATE; PRIORITY JOURNAL; PRODUCT SAFETY; RISK ASSESSMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; EUROPEAN UNION; HUMANS; PHARMACEUTICAL PREPARATIONS; PRIMATES;

EID: 84885583466     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2709     Document Type: Article

References (12)

1. Teelmann, K., Hohbach, C. & Lehmann, H. Arch. Toxicol. 59, 195-200 (1986).
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1997). Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals http://www. ich. org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Safety/S6-R1/Step4/S6-R1- Guideline. pdf (ICH, 1997).
3. Bailey, J., Capaldo, T., Conlee, K., Thew, M. & Pippin, J. Nat. Med. 14, 1011-1012; discussion 1012-1013 (2008).
4. European Medicines Agency. http://www. ema. europa. eu/ema/index. jsp?curl=pages/medicines/ human/medicines/000240/human-med-001023. jsp&mid=WC0b01ac058001d124 (EMA, 2008).
5. European Medicines Agency. http://www. ema. europa. eu/ema/index. jsp?curl=pages/medicines/ human/medicines/000582/human-med-000663. jsp&mid=WC0b01ac058001d124# (EMA, 2006).
6. Fraser, H. M. & Wulff, C. Reprod. Biol. Endocrinol. 1, 88 (2003).
7. European Medicines Agency. http://www. ema. europa. eu/docs/en-GB/ document-library/EPAR-Public- assessment-report/human/000972/WC500051808. pdf (EMA, 2009).
8. European Medicines Agency. http://www. ema. europa. eu/docs/en-GB/ document-library/EPAR-Public- assessment-report/human/001109/WC500031679. pdf (EMA, 2009).
9. European Medicines Agency. http://www. ema. europa. eu/docs/en-GB/ document-library/EPAR-Scientific- Discussion/human/000715/WC500043550. pdf (EMA, 2007).
10. European Medicines Agency. http://www. ema. europa. eu/docs/en-GB/ document-library/EPAR-Scientific- Discussion/human/000353/WC500025264. pdf (EMA, 2005).
11. European Medicines Agency. http://www. ema. europa. eu/docs/en-GB/ document-library/EPAR-Public- assessment-report/human/001037/WC500069735. pdf (EMA, 2009).
12. European Medicines Agency. http://www. ema. europa. eu/docs/en-GB/ document-library/EPAR-Scientific- Discussion/human/000603/WC500044690. pdf (EMA, 2007).